Table 2.

Treatment response to bintrafusp alfa

Efficacy (N = 30)	Independent review committee	Investigator
Confirmed best overall response, n (%)
Complete response	0	0
Partial response	6 (20.0)	4 (13.3)
Stable disease	4 (13.3)	7 (23.3)
Progressive disease	15 (50.0)	12 (40.0)
Not evaluable	5 (16.7)	7 (23.3)
Confirmed ORR, n (%)	6 (20.0)	4 (13.3)
95% CI	7.7–38.6	3.8–30.7
DCR, n (%)	10 (33.3)	11 (36.7)
95% CI	17.3–52.8	19.9–56.1
Median duration of response, months (range)	4.3 (1.3–8.3)	NR (3.6–12.6)
ORR by tumor cell PD-L1 expression, n/N (%)a
Positive	1/9 (11.1)	0/9 (0)
Negative	4/20 (20.0)	4/20 (20.0)
Not evaluable	1/1 (100)	0/1 (0)

DCR disease control rate, NR not reached, ORR objective response rate

^aA threshold of 1% was used to characterize tumors as either PD-L1 positive (≥ 1%) or negative (< 1%) using an anti-PD-L1 antibody clone 73-10